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What’s in a name? the history of medicine is replete with eponyms saluting a scientist’s discovery of a disease. 
However, it is unusual that the strength of this 
association results in the use of a pioneer’s name for 
a contrasting disease. Perhaps this singular distinction 
has been achieved through the continued use of the 
eponymous ‘Hodgkin’ for two types of lymphomas: 
Hodgkin and non-Hodgkin. The first of this two-
part tale of lymphomas is devoted to the original 
category, which was named Hodgkin’s disease, and 
is today called Hodgkin lymphoma (HL). It all began 
with a basic dilemma: was this disease an infection, 
inflammation or tumour? 
The Pioneers
In 1666, Marcell Malpighi was one of the first 
physicians to be credited with describing HL, 
observed during the autopsy of an 18-year-old female, 
in his publication: De viscerum structura exercitatio 
anatomica.1,2 Centuries later, in 1832, a paper was read 
to the Medical and Chirurgical Society in London, 
UK, on behalf of Thomas Hodgkin. It described seven 
patients with painless enlargement of the lymph nodes 
and included autopsy findings and illustrations from 
one of the patients given to the author by Robert 
Carswell.1,3 The author, Thomas Hodgkin (1798‒1866) 
of Guy’s Hospital, London, went on to publish a paper 
entitled: On some morbid cases of the absorbent glands 
and spleen. 
At this time, autopsies were an irreplaceable 
source of knowledge for understanding diseases; it is 
no wonder that in his appointment as ‘Inspector of 
the Dead’ Hodgkin was an astounding contributor to 
the Museum at Guy’s Hospital.4 Interest in this disease 
grew when Richard Bright published Observations on 
abdominal tumours and intumescence illustrated by 
cases of disease of the spleen in 1838, linking the spleen 
to the disease beyond its primary nodal origins.2
In 1856, Samuel Wilks observed similar cases and 
later, in 1865, published Cases of lardaceous diseases 
and some allied affections with remarks.5 In the true 
spirit of peer recognition, he honoured Hodgkin by 
eponymously referring to this disease as Hodgkin’s 
lymphoma.6 It is notable that neither Hodgkin nor 
Wilks supported the diagnosis of this new disease 
by its microscopic appearance, something that 
would be unthinkable today when the diagnostic 
world demands no less proof than morphology, 
immunohistochemistry and, in many cases, molecular 
genetics. From the archival tissues of Hodgkin’s original 
cases available today, only two were authenticated by 
immunophenotyping.1
In 1872 and 1878, Langhan and Greenfield, 
respectively, provided microscopic descriptions of HL; 
however the cells that came to typify the diagnosis, 
Reed-Sternberg (R-S) cells, were attributed to 
observations and illustrations made by Carl Sternberg 
in 1898 and Dorothy Reed in 1902.7,8 Despite Reed’s 
unique diagnostic contribution to pathology, as well 
as her work in distinguishing Hodgkin disease from 
tuberculosis, Reed went on to become a paediatrician. 
Her prospects of joining the academic ranks in 
pathology at Johns Hopkins School of Medicine as 
a woman were not in keeping with the prevailing 
attitudes of the time!9
Microscopy, at that time, became the gold 
standard for diagnosis as reviews of reported cases 
based on macroscopy alone showed that some cases 
may have been caused by other lymphomas or other 
prevalent infections like tuberculosis or syphilis. The 
dramatic illustration of the bulky lymphadenopathy in 
a prototype soldier-patient, and the original drawings 
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of the R-S cells by Reed were sourced from an article 
in the Annals of Diagnostic Pathology entitled The 
Original Illustrations of Hodgkin’s Disease.9,10 These 
images remind us of the painstaking methods adopted 
to preserve medical knowledge only a little over a 
century ago [Figures 1 and 2].10–12
More than a hundred years after these microscopic 
recordings, generations of pathologist physicians 
have been avid hunters of the large cells: Hodgkin, 
R-S or their variants. The pathology lexicon offered 
handy descriptors of these cells, like ‘popcorn’, 
‘owl-eye’, ‘mirror-image’, ‘lacunar’ or ‘mummified’, 
based on nuclear configurations. At a time when 
cut and dried combinations of lineage-specific 
immunohistochemical markers and molecular genet-
ics have become the cornerstone of haematolymphoid 
disease diagnosis, these time-honoured epithets have 
yet to be relegated to extinction.
Cell of Origin, Classifications 
and Cause
The neoplastic nature of HL was suggested by Gall 
and Mallory (1942), but scientifically grounded 
through cytogenetics and clonality in 1967 and 1975 
by Boecker, Seif and their collaborators.13–15 In 1999 
Cossmann and colleagues, through a detailed genomic 
analysis, narrowed down the origin of the R-S cell to 
germinal centre B cell type.16
Once a disease is identified, the classification-
conscious scientific mind wastes no time in devising 
categories to separate clinically-relevant disease 
subsets based on appearance and outcome. In 1947, 
after a lag period of nearly half a century since 
HL came to be recognised as an entity, the first 
classification, the Jackson and Parker classification, 
appeared. This classification identified three groups: 
Hodgkin’s paragranuloma, granuloma and sarcoma. 
Paragranulomas represented cases with few atypical 
cells and an indolent course, granulomas described 
cases with usual appearance and progression, and 
sarcomas represented bizarre cytology and aggressive 
behaviour.17 Lukes’ and Butler’s initial classification 
recommended six groups: lymphocytic and/or 
histiocytic, nodular; lymphocytic and/or histiocytic, 
diffuse; nodular sclerosis; mixed; diffuse fibrosis, and 
reticular.18 These classifications were later streamlined 
to four categories: lymphocyte predominance; 
nodular sclerosis; mixed cellularity, and lymphocytic 
depletion.19 In 1994, in a dramatic immunophenotype-
based approach to haematolymphoid malignancies, 
the Revised European-American Lymphoma classification 
separated nodular lymphocyte-predominant HL (nLPHL) 
from classical HL (cHL).20 More recently, in 2001 and 2008, 
the World Health Organization classification has endorsed 
a category of a lymphocyte-rich cHL.21,22
Much of the evolution in terminology and 
classification originates from gradual revelation of 
the lymphoma’s cell of origin. Unlike most other 
malignancies, HL-affected nodes show an interesting 
admix of several types of inflammatory and lymphoid 
cells. In the last four decades there has been 
clarification in the form of the exponential growth 
of cluster designate (CD) markers, which identify 
 
Figure 1: An original illustration of a patient with 
Hodgkin’s disease.10,11
 
Figure 2: Dorothy Reed’s drawings of what came to be 
referred to as Reed-Sternberg cells.10,12
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Treatment: Empirical to 
targeted
In 1832, Hodgkin tried to treat one of his patients 
with cascarilla, soda and iodine with an obvious lack 
of success, since this patient along with six others 
became the subject of an autopsy.1 In 1894, Fowler’s 
solution, which originally contained potassium 
arsenite when it was concocted in 1786 by Thomas 
Fowler, demonstrated some success,26 and earned its 
place in Osler’s Textbook of Medicine.2 In the 1940s, 
nitrogen mustard, the gas that gained notoriety for its 
wartime usage, was included as a therapeutic option 
by Goodman et al., following its successful use for 
other haematolymphoid malignancies.27
Though radiotherapy was first used for this 
disease in 1902,28 it was in 1932 that Chevalier and 
Bernard recommended radiotherapy for palliation.29 
This became popular in the 1940s and reached a 
pinnacle in the 1960s.29 The important concept that 
Hodgkin’s disease involved lymph nodes by contiguity 
was proposed by radiotherapists Rene Gilbert 
(Switzerland) and Vera Peters (Canada) in the 1950s, 
providing the opportunity to offer planned, targeted 
coverage to the affected nodes.28
In 1955, Henry Kaplan, working at Stanford 
University Medical Center, used a six million volt 
medical linear accelerator for the first time on a child 
with retinoblastoma. Following its success, he turned 
his attention to using it for Hodgkin’s disease.30 His 
pioneering efforts with radiotherapy not only changed 
the cancer landscape but transformed Hodgkin’s 
disease from invariably fatal to near-curable.
The dominance of radiotherapy continued until 
chemotherapy entered the cancer arena and Hodgkin’s 
disease became the ‘poster boy’ for success in cancer 
treatment. The ground was laid through the discoveries 
of individual drugs, chlorambucil and vincristine. 
Soon enough the movement was galvanised by the 
concept of combination chemotherapy to achieve 
maximum benefit. In 1964, a four-drug combination 
of mustine hydrochloride, vincristine, procarbazine 
and prednisone (MOPP) was tested at the National 
Cancer Institute. By 1970, MOPP was shown to 
achieve cure rates of 70%, even in patients with 
advanced stage disease.31,32 Patients lived longer, and 
the long-term side-effects became apparent. Sterility 
due to procarbazine and second malignancies due 
to nitrogen mustard threatened to offset the gains 
achieved. In 1981, another four-drug combination of 
doxorubicin, bleomycin, vinblastine and dacarbazine 
(ABVD), designed at the Istituto Nazionale dei Tumori 
in Milan, Italy, relegated MOPP to history.33 The cure 
rates were higher with ABVD and the long-term 
antigen-based lineage of haematolymphoid cells, and 
gene expression profiling. Thus far, the fulcrum rests 
on a follicular centre B cell origin for the nLPHL, while 
the subsets of cHL are linked to post-germinal centre 
B cells.23 It is intriguing to note that these transformed 
B cells have actually lost their capacity to differentiate 
or respond to antigenic stimuli. The attendant 
combination of granulocytes (neutrophils, eosinophils) 
confer a polymorphic microscopic cocktail. They have 
been attributed to the secretion of chemoattractant 
cytokines by the neoplastic cells. Inflammation also 
explains the ‘B’ symptoms that often bring the patient 
to the hospital in the first place.24
The systematic evolution of understanding 
pathobiology has shaped clinicopathologic entities 
and outcome determination in HL, with mixed 
cellularity HL and lymphocyte depletion HL being 
the worst. Current prognostication, however, relies 
more emphatically on the disease stage, B symptoms 
and concurrent association with other conditions, 
such as immunodeficiency.25 It is certain that the last 
word on classification has yet to be written, with the 
spectre of ‘grey-zone’ lymphomas, overlapping HL and 
non-HL, providing fodder for researchers.25 Genome 
sequencing may provide new historical landmarks for 
future medical generations.
Epstein-Barr virus (EBV) DNA was first reported 
in the R-S cells of a proportion of HL cases in 1987. 
Since 1990, the identification of EBV-encoded 
ribonucleotides (RNAs) 1 and 2 is the gold standard 
for its demonstration in clinical tissues.16 The 
association gained further momentum from the fact 
that HL associated with human immunodeficiency 
virus infection has a high frequency of detection of 
EBV RNAs in the R-S cells.
Surgery-Radiology Set the 
Stage for Staging
An important basis of rational treatment was set 
in motion in the Rye (1966) and Ann Arbor (1971) 
expert meetings of the Committee of Staging and 
Classification of Hodgkin’s Disease, when staging 
systems and pathological categories determined 
treatment options and prognoses. Initially, radical 
surgery such as splenectomy, liver biopsy and 
retroperitoneal lymph node sampling provided 
proof of infradiaphragmatic involvement. This was 
further expanded by lymphangiography. Only a 
few decades later, these substantive explorations 
appear unnecessary and invasive, with the advent of 
computerised tomography (CT) scans and positron 
emission tomography (PET).
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side-effects were fewer. Such was the success that the 
10–30% failure rate was considered a major challenge. 
The last 30 years have seen efforts to refine 
treatment through the identification of prognostic 
factors. Besides the prognostic factors at presentation,34 
early metabolic response to chemotherapy assessed by 
PET-CT scan has changed the landscape.35 It is now 
possible to achieve durable responses and high cure 
rates through strategies such as reduction of doses, 
drugs and number of cycles of chemotherapy for 
good prognostic groups.36 On the other hand, more 
extensive combinations, such as bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarb-
azine and prednisone from the German Hodgkin Study 
Group and the Stanford V regimen from the Eastern 
Cooperative Oncology Group have helped to improve 
the cure rates in poor prognostic groups.37,38 Even 
patients who do not achieve a complete remission at 
the end of treatment, as well as those who relapse after 
achieving a complete remission, still stand a chance of 
being cured. High-dose chemotherapy and autologous 
stem cell transplantation have been shown to produce 
lasting remissions in 10–60% of patients.39 Optimisation 
of treatment has continued to evolve both in search of 
less toxic treatment for good prognostic patients and 
additional treatment for the poor prognostic patients. 
Examples of history-in-the-making molecules include 
anti-CD20 antibody rituximab for nLPHL,40 and the 
chemoimmunoconjugate, brentuximab vedotin, for 
cHL and a variety of other CD 30-positive tumours.41 
Lessons from the History of 
Hodgkin Lymphoma
The centuries stand witness to the fascinating 
contributions of physicians, pathologists, radiothera-
pists and geneticists rising to the challenge of 
conquering this haematolymphoid malignancy. 
From clinical manifestations to interesting cell 
appearances, they are an acknowledgement of the 
times when discerning physicians used basic tools of 
observation and analysis to define diseases. They also 
tell a story of unprecedented forays in cell biology 
(molecular genetics), opportunity (nitrogen mustard), 
success (radiotherapy) and cure (chemotherapy)—
each a reflection of the rapid evolution in science 
and technology that is the hallmark of the last two 
centuries. It is also a promising example of the concept 
that many cancers are now considered curable or 
chronic rather than fatal diseases.
This tale concludes by urging the reader to 
learn more about the persona, character, beliefs and 
global influence of Thomas Hodgkin, in a brilliant, 
personalised narrative of his life and times, delivered 
at his bicentennial in 1998.42 His life is epitomised by 
the epitaph on his grave:
Humani nihil a se alienum putabat (Nothing of 
humankind was foreign to him).
References
1. Banerjee D. Recent insights into the biology of Hodgkin’s 
lymphoma. From: cdn.intechopen.com/pdfs-wm/33669.pdf 
Accessed: Jan 2015.
2. LymphomaInfo.net. Hodgkin's Disease: Historical timeline. From: 
www.lymphomainfo.net/hodgkins/timeline.html  Accessed: Jan 
2015.
3. Hodgkin T. On some morbid appearances of the absorbent 
glands and spleen. Med Chir Trans 1832; 17:68–114.
4. Daws JJ. Thomas Hodgkin and the museum at Guy’s hospital. 
Cancer Treat Rev 1999; 25:145–50. doi: 10.1053/ctrv.1998.0110.
5. Hummel M. World Health Organization and beyond: New 
aspects in the pathology of an old disease. Hematol Oncol Clin 
North Am 2007; 21:769–86. doi: 10.1016/j.hoc.2007.06.015.
6. Wilks S. Cases with enlargement of the lymphatic glands and 
spleen (or Hodgkin’s disease) with remarks. Guys Hosp Rep 
1865; 1:57.
7. Sternberg C. Über eine eigenartige unter dem Bilde der 
Pseudoleukämie verlaufende Tuberculose des lymphatischen 
Apparates Ztschr Heilk 1898; 19:21–90.
8. Reed DM. On the pathological changes in Hodgkin's disease, 
with special reference to its relation to tuberculosis. John 
Hopkins Hosp Rep 1902; 10:133–96.
9. Dawson PJ. Whatever happened to Dorothy Reed? Ann Diagn 
Pathol 2003; 7:195–203. doi: 10.1016/S1092-9134(03)00020-0.
10. Dawson PJ. The original illustrations of Hodgkin’s disease. 
Ann Diagn Pathol 1999; 3:386–93. doi: 10.1016/S1092-
9134(99)80018-5.
11. Porter JH. Two cases of Hodgkin’s disease of the glands: 
Leucocythaemia; Lymphadenosis. Trans Path Soc Lond 1878; 
29:335–41. 
12. Reed DM. On the pathological changes in Hodgkin’s disease, 
with special reference to its relation to tuberculosis. Johns 
Hopkins Hosp Rep 1902; 10:113–96.
13. Gall EA, Mallory TB. Malignant lymphoma: A clinico-
pathologic survey of 618 cases. Am J Pathol 1942; 18:381–429.
14. Seif GS, Spriggs AI. Chromosome changes in Hodgkin's disease. 
J Natl Cancer Inst 1967; 39:557–70. doi: 10.1093/jnci/39.3.557.
15. Boecker WR, Hossfeld DK, Gallmeier WM, Schmidt CG. 
Clonal growth of Hodgkin cells. Nature 1975; 258:235–6. doi: 
10.1038/258235a0.
16. Kapatai G, Murray P. Contribution of the Epstein Barr virus 
to the molecular pathogenesis of Hodgkin lymphoma. J Clin 
Pathol 2007; 60:1342–9. doi: 10.1136/jcp.2007.050146.
17. Jackson H, Parker F, Eds. Hodgkin’s Disease and Allied 
Disorders. New York, USA: Oxford University Press, 1974.
18. Lukes RJ, Butler J, Hicks EB. [The prognosis of Hodgkin's 
disease according to the histologic type and the clinical stage. 
Role of the reactions of the host]. Nouv Rev Fr Hematol 1966; 
6:15–22.
19. Lukes RJ, Butler JJ. The pathology and nomenclature of 
Hodgkin's disease. Cancer Res 1966; 26:1063–83.
20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, 
et al. A revised European-American classification of lymphoid 
neoplasms: A proposal from the International Lymphoma 
Study Group. Blood 1994; 84:1361–92.
A Historical Tale of Two Lymphomas 
Part I: Hodgkin lymphoma
e206 | SQU Medical Journal, May 2015, Volume 15, Issue 2
33. Bonadonna G, Zucali R, Monfardini S, De Lena M, 
Uslenghi C. Combination chemotherapy of Hodgkin’s 
disease with adriamycin, bleomycin, vinblastine, and 
imidazole carboxamide versus MOPP. Cancer 1975; 
36:252–9. doi: 10.1002/1097-0142(197507)36:1<252::AID-
CNCR2820360128>3.0.CO;2-7.
34. Hasenclever D, Diehl V. A prognostic score for advanced 
Hodgkin's disease. International Prognostic Factors Project on 
Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506–14. 
doi: 10.1056/NEJM199811193392104.
35. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, 
Jurlander J, et al. FDG-PET after two cycles of chemotherapy 
predicts treatment failure and progression-free survival in 
Hodgkin lymphoma. Blood 2006; 107:52–9. doi: 10.1182/
blood-2005-06-2252.
36. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, 
Borchmann P, et al. Reduced treatment intensity in patients 
with early-stage Hodgkin’s lymphoma. N Engl J Med 2010; 
363:640–52. doi: 10.1056/NEJMoa1000067.
37. Diehl V, Franklin J, Hasenclever D,  Tesch H, Pfreundschuh 
M, Lathan B, et al. BEACOPP: A new regimen for advanced 
Hodgkin’s disease. German Hodgkin’s Lymphoma Study 
Group. Ann Oncol 1998; 9:S67–71. doi: 10.1093/annonc/9.
suppl_5.S67.
38. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, 
Rosenberg SA. Stanford V and radiotherapy for locally 
extensive and advanced Hodgkin’s disease: Mature results of 
a prospective clinical trial. J Clin Oncol 2002; 20:630–7. doi: 
10.1200/JCO.20.3.630.
39. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, 
Haenel M, et al. Aggressive conventional chemotherapy 
compared with high-dose chemotherapy with autologous 
haemopoietic stem-cell transplantation for relapsed 
chemosensitive Hodgkin’s disease: A randomised trial. Lancet 
2002; 359:2065–71. doi: 10.1016/S0140-6736(02)08938-9.
40. Horning SJ, Bartlett NL, Breslin S, Advani RH, Hoppe RT, 
Ekstrand BC, et al. Results of a prospective phase II trial 
of limited and extended rituximab treatment in nodular 
lymphocyte predominant Hodgkin’s disease (NLPHD). Blood 
2007; 110:644.
41. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, 
Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed 
CD30-positive lymphomas. N Engl J Med 2010; 363:1812–21. 
doi: 10.1056/NEJMoa1002965.
42. Kass AM. Thomas Hodgkin remembered. Cancer Treat Rev 
1999; 25:133–143. doi: 10.1053/ctrv.1998.0108.
21. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health 
Organization classification of tumours: Pathology and genetics 
of tumours of haematopoietic and lymphoid tissues. Ann Oncol 
2002; 13:490–1. doi: 10.1093/annonc/mdf146.
22. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, 
et al. WHO Classification of Tumours of Haematopoietic and 
Lymphoid Tissues. Lyon, France: IARC Press, 2008. 
23. Mani H, Jaffe ES. Hodgkin lymphoma: An update on its 
biology with newer insights into classification. Clin Lymphoma 
Myeloma 2009; 9:206–16. doi: 10.3816/CLM.2009.n.042.
24. Allemani C, Sant M, De Angelis R, Marcos-Gragera R, 
Coebergh JW; Eurocare Working Group. Hodgkin disease 
survival in Europe and the U.S: Prognostic significance of 
morphologic groups. Cancer 2006; 107:352–60. doi: 10.1002/
cncr.21995.
25. Harris NL. Shades of gray between large B-cell lymphomas 
and Hodgkin lymphomas: Differential diagnosis and biological 
implications. Mod Pathol 2013; 26:S57–70. doi: 10.1038/
modpathol.2012.182.
26. Waxman S, Anderson KC. History of the development of 
arsenic derivatives in cancer therapy. Oncologist 2001; 6:S3–10. 
doi: 10.1634/theoncologist.6-suppl_2-3.
27. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, 
Gilman A, Mclennan MT. Nitrogen mustard therapy: Use of 
methyl-bis (beta-chloroethyl) amine hydrochloride and tris 
(beta-chloroethyl) amine hydrochloride for Hodgkin's disease, 
lymphosarcoma, leukemia and certain allied and miscellaneous 
disorders. J Am Med Assoc 1946; 132:126–32. doi: 10.1001/
jama.1946.02870380008004. 
28. DeVita VT Jr. A selective history of the therapy of Hodgkin’s 
disease. Br J Haematol 2003; 122:718–27. doi: 10.1046/j.1365-
2141.2003.04541.x.
29. Chevalier P, Bernard J. La Maladie de Hodgkin (Lymphog-
ranulomatose Maligne). Paris, France: Mason et Cie, 1932.
30. Jacobs CD. Henry Kaplan and the Story of Hodgkin’s Disease. 
Redwood City, California, USA: Stanford University Press, 
2010.
31. DeVita VT Jr, Serpick AA, Carbone PP. Combination 
chemotherapy in the treatment of advanced Hodgkin’s disease. 
Ann Intern Med 1970; 73:881–95. doi: 10.7326/0003-4819-73-
6-881.
32. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard 
CW, Moxley JH 3rd, et al. Curability of advanced Hodgkin’s 
disease with chemotherapy: Long-term follow-up of MOPP-
treated patients at the National Cancer Institute. Ann Intern 
Med 1980; 92:587–95. doi: 10.7326/0003-4819-92-5-587.
